An overdose of eflapegrastim may result in leukocytosis and bone pain.L43135 In the event of an overdose, the patient should be monitored for adverse effects and general supportive measures should be implemented as necessary.
Febrile neutropenia (FN), defined as the co-occurrence of fever (temperature > 38 ?C) and severe neutropenia (ANC < 500 cells/mm3), is a potential side effect of myelosuppressive chemotherapy in which the patient develops an infection during a period of significant neutropenia.A252320 It typically develops during the first cycle of chemotherapy and is associated with an increased risk of morbidity and mortality. The primary factor associated with FN risk is the chemotherapy regimen being administered - regimens are classified as either high-, intermediate-, or low-risk for FN, and relevant guidelines recommend the use of pharmacologic prophylaxis against FN in patients receiving high-risk regimens and those receiving intermediate-risk regimens who have ?1 additional risk factor.A252320
Granulocyte-colony stimulating factors (G-CSFs) - which include filgrastim and pegfilgrastim - were first used clinically in the 1990s and are the primary means of prophylaxis against chemotherapy-induced neutropenia, including FN.A252320 They trigger signaling pathways that control the differentiation, proliferation, migration, and survival of neutrophils, thereby helping to restore depressed neutrophil counts.L43135
Eflapegrastim is a form of recombinant human G-CSF comprising a human G-CSF analog coupled to the Fc fragment of human IgG4 via a polyethylene glycol linker.L43135 In September 2022, eflapegrastim was approved by the US FDA as a prophylactic against infection, as manifested by febrile neutropenia, in patients receiving certain myelosuppressive anti-cancer drugs.L43170
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Cyclophosphamide | The risk or severity of pulmonary toxicity can be increased when Eflapegrastim is combined with Cyclophosphamide. |
| Topotecan | The risk or severity of neutropenia can be increased when Eflapegrastim is combined with Topotecan. |
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Eflapegrastim. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Eflapegrastim. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Eflapegrastim. |
| Estrone | Estrone may increase the thrombogenic activities of Eflapegrastim. |
| Estradiol | Estradiol may increase the thrombogenic activities of Eflapegrastim. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Eflapegrastim. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Eflapegrastim. |
| Mestranol | Mestranol may increase the thrombogenic activities of Eflapegrastim. |
| Estriol | Estriol may increase the thrombogenic activities of Eflapegrastim. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Eflapegrastim. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Eflapegrastim. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Eflapegrastim. |
| Tibolone | Tibolone may increase the thrombogenic activities of Eflapegrastim. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Eflapegrastim. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Eflapegrastim. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Eflapegrastim. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Eflapegrastim. |
| Zeranol | Zeranol may increase the thrombogenic activities of Eflapegrastim. |
| Equol | Equol may increase the thrombogenic activities of Eflapegrastim. |
| Estetrol | Estetrol may increase the thrombogenic activities of Eflapegrastim. |
| Promestriene | Promestriene may increase the thrombogenic activities of Eflapegrastim. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Eflapegrastim. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Eflapegrastim. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Eflapegrastim. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Eflapegrastim. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Eflapegrastim. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Eflapegrastim. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Eflapegrastim. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Eflapegrastim. |
| Formononetin | Formononetin may increase the thrombogenic activities of Eflapegrastim. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Eflapegrastim. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Eflapegrastim. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Eflapegrastim. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Eflapegrastim. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Eflapegrastim. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Eflapegrastim. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Eflapegrastim. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Eflapegrastim. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Eflapegrastim. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Eflapegrastim. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Eflapegrastim. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Eflapegrastim. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Eflapegrastim. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Eflapegrastim. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Eflapegrastim. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Eflapegrastim. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Eflapegrastim. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Eflapegrastim. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Eflapegrastim. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Eflapegrastim. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Eflapegrastim. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Eflapegrastim. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Eflapegrastim. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Eflapegrastim. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Eflapegrastim. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Eflapegrastim. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Eflapegrastim. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Eflapegrastim. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Eflapegrastim. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Eflapegrastim. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Eflapegrastim. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Eflapegrastim. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Eflapegrastim. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Eflapegrastim. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Eflapegrastim. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Eflapegrastim. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Eflapegrastim. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Eflapegrastim. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Eflapegrastim. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Eflapegrastim. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Eflapegrastim. |
| Hepatitis B immune globulin | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Eflapegrastim. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Eflapegrastim. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Eflapegrastim. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Eflapegrastim. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Eflapegrastim. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Eflapegrastim. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Eflapegrastim. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Eflapegrastim. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Eflapegrastim. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Eflapegrastim. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Eflapegrastim. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Eflapegrastim. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Eflapegrastim. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Eflapegrastim. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Eflapegrastim. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Eflapegrastim. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Eflapegrastim. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Eflapegrastim. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Eflapegrastim. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Eflapegrastim. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Eflapegrastim. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Eflapegrastim. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Eflapegrastim. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Eflapegrastim. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Eflapegrastim. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Eflapegrastim. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Eflapegrastim. |